Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for induction of clinical remission in moderate to severe Crohn's disease patients who lost response or are intolerant to infliximab
2004-002934-20Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Adalimumab (Humira) with Placebo (2 arms). Primary endpoint: Induction of clinical remission at week 4. Started Jul 2005; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2004-002934-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002934-20.